Open Nav

Innova Therapeutics

  • Robert Ryan, Innova Therapeutics

Attract investors to participate in completion of the Series A round

  • Date:Wednesday, October 17
  • Time:11:15 AM - 11:30 AM
  • Room:Olympic
  • Location:2nd Floor
  • Session Type:Company Presentation
  • Presentation Type:Privately Funded Company
  • Company Description/Mission Statement:Innova Therapeutics is a dedicated biotech developing innovative therapies for people living with rare diseases, for which there are no effective treatments. There are two novel programs, one at the late pre-IND stage for topical and systemic treatment of inflammatory/autoimmune diseases and another completed Phase 2 in two genetic diseases (OPMD and SCA). Innova Therapeutics is comprised of executives who previously founded and developed a topical therapy for Epidermolysis Bullosa for Scioderm. The management team moved the development of a topical therapy from Pre-IND to Phase 3 in less than 2 years, resulting in partnering the company in 2015 as the 4th highest VC-backed exit (spent $22M and total deal structure appr. $957M). Scioderm was the first biotech company to receive Breakthrough therapy designation and listed as one of the most promising Biotechs by Fierce Biotech (Fierce 15).
  • Company Website:under construction
  • Company HQ City:Isle of Palms
  • Company HQ Country:United States
  • Company HQ State:South Carolina       
  • CEO/Top Company Official:Dr Robert Ryan
  • Year Founded:2016
  • Main Therapeutic Focus:Orphan/Rare Diseases
  • Lead Product in Development :Systemic Therapy for OPMD, topical therapy for Epidermolysis Bullosa
  • Development Phase of Primary Product:Phase III
  • Previous and Current Investors:Morgenthaler, Technology Partners, Redmile
  • Size of Last Investment Round:Scioderm - last round $20M
  • Total Amount Raised to Date, In All Rounds:currently raising Series A of $25M
Robert Ryan
Innova Therapeutics